Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)

Current Therapeutic Research - Clinical and Experimental

Volumn 66, Issue 2, 2005, Pages 80-95

  Teramoto, Tamio ^a   Kashiwagi, Atsunori ^b   Mabuchi, Hiroshi ^c   Aso, Masako ^d  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d Kyoto Institute of Technology   (Japan)

Author keywords

Achievement rates for management goals; Guidelines; HMG CoA reductase inhibitors; Hyperlipidemia; J LAP; Lipid lowering therapy; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DATA ANALYSIS; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG EFFICACY; ETHNIC GROUP; EVALUATION; FAMILIAL HYPERLIPEMIA; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CENTER; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; JAPAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 20444380978     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.04.004     Document Type: Article

References (24)

1. Kannel W.B., Castelli W.P., Gordon T., and McNamara P.M. Serum cholesterol, lipoproteins, and risk of coronary heart disease. The Framingham Study Ann Intern Med. 74 1971 1 12
2. Stamler J., Wentworth D., and Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 1986 2823 2828
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
5. Matsuzaki M., Kita T., Mabuchi H. J-LIT Study Group, Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy inJapanese patients with hypercholesterolemia Circ J. 66 2002 1087 1095
6. Mabuchi H., Kita T., Matsuzaki M. J-LIT Study Group, Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy inJapanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT) Circ J. 66 2002 1096 1100
7. Hata Y., Mabuchi H., and Saito Y. Guideline for diagnosis and treatment of hyperlipidemia in adults [in Japanese] Domyakukoka 25 1997 1 34
8. Hata Y., Mabuchi H., and Saito Y. Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults J Atheroscler Thromb. 9 2002 1 27
9. Saito Y. Editorial: Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 2002 J Atheroscler Thromb. 11 2004 101 103
10. Mabuchi H., Inazu A., and Higashikata T. The current status of medicinal therapy for hyperlipidemia-Kanazawa Lipid Assessment Survey (K-LAS) [in Japanese] Prog Med. 20 2000 1629 1639
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
12. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem. 18 1972 499 502
13. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med. 160 2000 459 467
14. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
15. Muls E., De Backer G., and De Bacquer D. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals Clin Drug Invest. 19 2000 219 229
16. International Task Force on the Prevention of Coronary Heart Disease Recommendation of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease Nutr Metab Cardiovasc Dis. 2 1992 113 156
17. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
18. Sever P.S., Dahlof B., and Poulter N.R. ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet 361 2003 1149 1158
19. Bellosta S., Ferri N., and Arnaboldi L. Pleiotropic effects of statins in atherosclerosis and diabetes Diabetes Care 23 Suppl 2 2000 1372 1378
20. [published correction appears in J Atheroscler Thromb. 2001;8:following 100] Ito H., Ouchi Y., and Ohashi Y. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The pravastatin anti-atherosclerosis trial in the elderly (PATE) J Atheroscler Thromb. 8 2001 33 44
21. Horiuchi H., Matsuzawa Y., and Mabuchi H. Strategy for treating elderly Japanese with hypercholesterolemia Geriatr Gerontol Int. 4 2004 151 157
22. Dawber T.R., Kannel W.B., and Revotskie N. Some factors associated with the development of coronary heart disease: Six years' follow-up experience in the Framingham Study Am J Public Health 49 1959 1349 1356
23. Kannel W.B., Dawber T.R., and Kagan A. Factors of risk in the development of coronary heart disease-six year follow-up experience: The Framingham Study Ann Intern Med. 55 1961 33 50
24. Kannel W.B., Dawber T.R., and Friedman G.D. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study Ann Intern Med. 61 1964 888 899